METTL3 and hepatocellular carcinoma: RG7112-sensitized apatinib could demethylate p53 mRNA and reduce p53 mRNA binding to Mettl3, thereby increasing the transcriptional activity of p53 and enhancing its anticancer effect.[68] Lenvatinib is another first-line therapeutic option for advanced HCC.